<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36767283</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1660-4601</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>20</Day></PubDate></JournalIssue><Title>International journal of environmental research and public health</Title><ISOAbbreviation>Int J Environ Res Public Health</ISOAbbreviation></Journal><ArticleTitle>Cost Consequence Analysis of Belimumab versus Standard of Care for the Management of Systemic Lupus Erythematosus in Saudi Arabia: A Retrospective Cohort Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1917</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijerph20031917</ELocationID><Abstract><AbstractText Label="BACKGROUND">Belimumab use for the management of systemic lupus erythematosus (SLE) has been limited, in part due to its high acquisition cost relative to the standard of care (SoC) and the uncertainties about its cost-effectiveness. Therefore, the aim of this study was to compare the cost and effectiveness of belimumab versus the SoC alone for the management of SLE using real-world data from the perspective of public healthcare payers in Saudi Arabia.</AbstractText><AbstractText Label="METHODS">Data were retrieved from a national prospective cohort of SLE, Saudi Arabia. Adult SLE patients (&#x2265;18 yrs.) treated with belimumab plus the SoC or the SoC alone for at least six months were recruited. The effectiveness was measured using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). Unit costs for health services and prescription drugs were retrieved from the Saudi ministry of health. Nonparametric bootstrapping with inverse probability weighting was conducted to generate the 95% confidence limits for the cost and effectiveness.</AbstractText><AbstractText Label="RESULTS">A total of 15 patients on belimumab plus the SoC and 41 patients on the SoC alone met the inclusion criteria and were included in the analysis. The majority of patients were females (91.07%) with a mean age of 38 years. The mean difference in cost and SLEDAI-2K score reduction between belimumab versus the SoC were USD 5303.16 [95% CI: USD 2735.61-USD 7802.52] and 3.378 [95% CI: 1.769-6.831], respectively. Belimumab demonstrated better effectiveness but higher cost in 96% of the bootstrap cost-effectiveness distributions.</AbstractText><AbstractText Label="CONCLUSION">Future studies should use more robust research designs and a larger sample size to confirm the findings of this study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alsuwayegh</LastName><ForeName>Aseel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2131-0094</Identifier><AffiliationInfo><Affiliation>Corporate Department of Pharmacy Services, King Saud University Medical City, Riyadh 11451, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almaghlouth</LastName><ForeName>Ibrahim A</ForeName><Initials>IA</Initials><Identifier Source="ORCID">0000-0002-8176-287X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almasaoud</LastName><ForeName>Majed Ali</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-2097-3534</Identifier><AffiliationInfo><Affiliation>College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzaid</LastName><ForeName>Abdullah Sulaiman</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsuhaibani</LastName><ForeName>Adel Abdulaziz</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-2113-3430</Identifier><AffiliationInfo><Affiliation>College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almana</LastName><ForeName>Lyan Hassan</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alabdulkareem</LastName><ForeName>Sara Mohammed</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abudahesh</LastName><ForeName>Joud Abdullah</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AlRuthia</LastName><ForeName>Yazed</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0029-5924</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacoeconomics Research Unit, Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Environ Res Public Health</MedlineTA><NlmUniqueID>101238455</NlmUniqueID><ISSNLinking>1660-4601</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73B0K5S26A</RegistryNumber><NameOfSubstance UI="C511911">belimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="Y">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012529" MajorTopicYN="N" Type="Geographic">Saudi Arabia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059039" MajorTopicYN="N">Standard of Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Saudi Arabia</Keyword><Keyword MajorTopicYN="N">belimumab</Keyword><Keyword MajorTopicYN="N">cost effectiveness analysis</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Authors of this study have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36767283</ArticleId><ArticleId IdType="pmc">PMC9915237</ArticleId><ArticleId IdType="doi">10.3390/ijerph20031917</ArticleId><ArticleId IdType="pii">ijerph20031917</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Borchers A.T., Naguwa S.M., Shoenfeld Y., Gershwin M.E. The geoepidemiology of systemic lupus erythematosus. Autoimmun. Rev. 2010;9:A277&#x2013;A287. doi: 10.1016/j.autrev.2009.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2009.12.008</ArticleId><ArticleId IdType="pubmed">20036343</ArticleId></ArticleIdList></Reference><Reference><Citation>Cojocaru M., Cojocaru I.M., Silosi I., Vrabie C.D. Manifestations of systemic lupus erythematosus. Maedica. 2011;6:330&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391953</ArticleId><ArticleId IdType="pubmed">22879850</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscal E., Brey R.L. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol. Clin. 2010;28:61&#x2013;73. doi: 10.1016/j.ncl.2009.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2009.09.004</ArticleId><ArticleId IdType="pmc">PMC2981505</ArticleId><ArticleId IdType="pubmed">19932376</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr S.G., Zonana-Nacach A., Magder L.S., Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1999;42:2682&#x2013;2688. doi: 10.1002/1529-0131(199912)42:12&lt;2682::AID-ANR26&gt;3.0.CO;2-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199912)42:12&lt;2682::AID-ANR26&gt;3.0.CO;2-6</ArticleId><ArticleId IdType="pubmed">10616018</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R.R., Yen E.Y. SLE mortality remains disproportionately high, despite improvements over the last decade. Lupus. 2018;27:1577&#x2013;1581. doi: 10.1177/0961203318786436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318786436</ArticleId><ArticleId IdType="pmc">PMC6082727</ArticleId><ArticleId IdType="pubmed">30016928</ArticleId></ArticleIdList></Reference><Reference><Citation>Gergianaki I., Bortoluzzi A., Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract. Res. Clin. Rheumatol. 2018;32:188&#x2013;205. doi: 10.1016/j.berh.2018.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2018.09.004</ArticleId><ArticleId IdType="pubmed">30527426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulczycka L., Sysa-Jedrzejowska A., Robak E. Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations. Clin. Rheumatol. 2010;29:991&#x2013;997. doi: 10.1007/s10067-010-1509-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-010-1509-0</ArticleId><ArticleId IdType="pmc">PMC2908751</ArticleId><ArticleId IdType="pubmed">20532577</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakshi J., Segura B.T., Wincup C., Rahman A. Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Clin. Rev. Allergy Immunol. 2018;55:352&#x2013;367. doi: 10.1007/s12016-017-8640-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-017-8640-5</ArticleId><ArticleId IdType="pmc">PMC6244922</ArticleId><ArticleId IdType="pubmed">28853005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace D.J. Progress toward Better Treatment of Lupus. N. Engl. J. Med. 2022;387:939&#x2013;940. doi: 10.1056/NEJMe2208772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2208772</ArticleId><ArticleId IdType="pubmed">36069878</ArticleId></ArticleIdList></Reference><Reference><Citation>Basta F., Fasola F., Triantafyllias K., Schwarting A. Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. Rheumatol. Ther. 2020;7:433&#x2013;446. doi: 10.1007/s40744-020-00212-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-020-00212-9</ArticleId><ArticleId IdType="pmc">PMC7410873</ArticleId><ArticleId IdType="pubmed">32488652</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra S.V., Guzm&#xe1;n R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., Li E.K.M., Thomas M., Kim H.-Y., Le&#xf3;n M.G., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721&#x2013;731. doi: 10.1016/S0140-6736(10)61354-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61354-2</ArticleId><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzov&#xe1; D., Sanchez-Guerrero J., Schwarting A., Merrill J.T., Chatham W.W., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918&#x2013;3930. doi: 10.1002/art.30613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30613</ArticleId><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Neuner R., Thompson A., Pottackal G., Petullo D., Liu J., Nikolov N., Sahajwalla C., Doddapaneni S., Chen J. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective. Lupus. 2022;31:424&#x2013;432. doi: 10.1177/09612033221079771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221079771</ArticleId><ArticleId IdType="pubmed">35238725</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R., Rovin B.H., Houssiau F., Malvar A., Teng Y.K.O., Contreras G., Amoura Z., Yu X., Mok C.-C., Santiago M.B., et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N. Engl. J. Med. 2020;383:1117&#x2013;1128. doi: 10.1056/NEJMoa2001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K., Azmi S., Wu D., Goh A. Estimating the cost-effectiveness of belimumab versus standard care for sle patients in Hong Kong. Value Health. 2013;16:A117&#x2013;A118. doi: 10.1016/j.jval.2013.03.564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2013.03.564</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az-Cerezo S., Garc&#xed;a-Aparicio &#xc1;.M., Parrondo J., Vallejo-Aparicio L.A. Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain. Farm. Hosp. 2015;39:161&#x2013;170. doi: 10.7399/fh.2015.39.3.8814.</Citation><ArticleIdList><ArticleId IdType="doi">10.7399/fh.2015.39.3.8814</ArticleId><ArticleId IdType="pubmed">26005892</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrik O., Fotheringham J., Ren S., Tice J.A., Chapman R.H., Stevenson M.D., Pearson S.D., Herron-Smith S., Agboola F., Thokala P. The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States. Clin. J. Am. Soc. Nephrol. 2022;17:385&#x2013;394. doi: 10.2215/CJN.13030921.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.13030921</ArticleId><ArticleId IdType="pmc">PMC8975035</ArticleId><ArticleId IdType="pubmed">35115304</ArticleId></ArticleIdList></Reference><Reference><Citation>Almaghlouth I.A., Hassen L.M., Alahmari H.S., Bedaiwi A., Albarrak R., Daghestani M., Alqurtas E., Alkhalaf A., Bedaiwi M., Omair M., et al. National systemic lupus erythematosus prospective cohort in Saudi Arabia: A study protocol. Medicine. 2021;100:e26704. doi: 10.1097/MD.0000000000026704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000026704</ArticleId><ArticleId IdType="pmc">PMC8322486</ArticleId><ArticleId IdType="pubmed">34397699</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S., Isenberg D.A., Castrejon I. Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. Arthritis Care Res. 2020;72:27&#x2013;46. doi: 10.1002/acr.24221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24221</ArticleId><ArticleId IdType="pubmed">33091256</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D.D., Iba&#xf1;ez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 2002;29:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M., Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin. Exp. Rheumatol. 2006;24:S99&#x2013;S104.</Citation><ArticleIdList><ArticleId IdType="pubmed">17083771</ArticleId></ArticleIdList></Reference><Reference><Citation>Haukoos J.S., Lewis R.J. Advanced statistics: Bootstrapping confidence intervals for statistics with &#x201c;difficult&#x201d; distributions. Acad. Emerg. Med. 2005;12:360&#x2013;365. doi: 10.1197/j.aem.2004.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/j.aem.2004.11.018</ArticleId><ArticleId IdType="pubmed">15805329</ArticleId></ArticleIdList></Reference><Reference><Citation>General Assembly of the World Medical Association World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. J. Am. Coll. Dent. 2014;81:14&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">25951678</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarting A., Schroeder J.O., Alexander T., Schmalzing M., Fiehn C., Specker C., Perna A., Cholmakow-Bodechtel C., Koscielny V.B., Carnarius H. First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. Rheumatol. Ther. 2016;3:271&#x2013;290. doi: 10.1007/s40744-016-0047-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-016-0047-x</ArticleId><ArticleId IdType="pmc">PMC5127971</ArticleId><ArticleId IdType="pubmed">27804088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise L.M., Stohl W. Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents. Front. Med. 2020;7:303. doi: 10.3389/fmed.2020.00303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00303</ArticleId><ArticleId IdType="pmc">PMC7338653</ArticleId><ArticleId IdType="pubmed">32695790</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J.A., Shah N.P., Mudano A.S. Belimumab for systemic lupus erythematosus. Cochrane Database Syst. Rev. 2021 doi: 10.1002/14651858.CD010668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD010668</ArticleId><ArticleId IdType="pmc">PMC8095005</ArticleId><ArticleId IdType="pubmed">33631841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce I.N., O&#x2019;Keeffe A.G., Farewell V., Hanly J.G., Manzi S., Su L., Gladman D.D., Bae S.C., Sanchez-Guerrero J., Romero-Diaz J., et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann. Rheum. Dis. 2015;74:1706&#x2013;1713. doi: 10.1136/annrheumdis-2013-205171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205171</ArticleId><ArticleId IdType="pmc">PMC4552899</ArticleId><ArticleId IdType="pubmed">24834926</ArticleId></ArticleIdList></Reference><Reference><Citation>Urowitz M.B., Ohsfeldt R.L., Wielage R.C., Kelton K.A., Asukai Y., Ramachandran S. Organ damage in patients treated with belimumab versus standard of care: A propensity score-matched comparative analysis. Ann. Rheum. Dis. 2019;78:372&#x2013;379. doi: 10.1136/annrheumdis-2018-214043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214043</ArticleId><ArticleId IdType="pmc">PMC6390027</ArticleId><ArticleId IdType="pubmed">30610066</ArticleId></ArticleIdList></Reference><Reference><Citation>Samnaliev M., Barut V., Weir S., Langham J., Langham S., Wang X., Desta B., Hammond E. Health-care utilization and costs in adults with systemic lupus erythematosus in the United Kingdom: A real-world observational retrospective cohort analysis. Rheumatol. Adv. Pract. 2021;5:rkab071. doi: 10.1093/rap/rkab071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rap/rkab071</ArticleId><ArticleId IdType="pmc">PMC8493101</ArticleId><ArticleId IdType="pubmed">34622127</ArticleId></ArticleIdList></Reference><Reference><Citation>Libert C., Dejager L., Pinheiro I. The X chromosome in immune functions: When a chromosome makes the difference. Nat. Rev. Immunol. 2010;10:594&#x2013;604. doi: 10.1038/nri2815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2815</ArticleId><ArticleId IdType="pubmed">20651746</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez P., Mozo L., Guti&#xe9;rrez C., Su&#xe1;rez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: Gender and age influence on immunological features. Lupus. 2003;12:860&#x2013;865. doi: 10.1191/0961203303lu469xx.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu469xx</ArticleId><ArticleId IdType="pubmed">14667105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariburyo F., Xie L., Sah J., Li N., Lofland J.H. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States. J. Med. Econ. 2020;23:1&#x2013;9. doi: 10.1080/13696998.2019.1678170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2019.1678170</ArticleId><ArticleId IdType="pubmed">31589081</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokhandwala T., Coutinho A.D., Bell C.F. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus. Clin. Ther. 2021;43:1320&#x2013;1335. doi: 10.1016/j.clinthera.2021.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2021.06.009</ArticleId><ArticleId IdType="pubmed">34243966</ArticleId></ArticleIdList></Reference><Reference><Citation>AlRuthia Y., Alrashed S.A., Balkhi B., Aljamal M.S., Alsifri S., Alrumaih A.M., Alsabaan F., Alsaqa&#x2019;aby M., Al-Abdulkarim H.A., Altowaijri A.I. COVID-19 and Saudi Arabia public financing of prescription drugs: An opportunity for reform. Health Policy Technol. 2020 doi: 10.1016/j.hlpt.2020.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlpt.2020.10.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R., Moghadam-Kia S., LoMonico J., Okawa J., Coley C., Taylor L., Troxel A.B., Werth V.P. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch. Dermatol. 2011;147:203&#x2013;208. doi: 10.1001/archdermatol.2010.435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archdermatol.2010.435</ArticleId><ArticleId IdType="pmc">PMC3282059</ArticleId><ArticleId IdType="pubmed">21339447</ArticleId></ArticleIdList></Reference><Reference><Citation>Aberle T., Bourn R.L., Chen H., Roberts V.C., Guthridge J.M., Bean K., Robertson J.M., Sivils K.L., Rasmussen A., Liles M., et al. Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus. Lupus Sci. Med. 2017;4:e000176. doi: 10.1136/lupus-2016-000176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000176</ArticleId><ArticleId IdType="pmc">PMC5372139</ArticleId><ArticleId IdType="pubmed">28409015</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold T.B. Advances in lupus genetics. Curr. Opin. Rheumatol. 2015;27:440&#x2013;447. doi: 10.1097/BOR.0000000000000205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000205</ArticleId><ArticleId IdType="pmc">PMC4540605</ArticleId><ArticleId IdType="pubmed">26218512</ArticleId></ArticleIdList></Reference><Reference><Citation>Barliana M.I., Afifah N.N., Amalia R., Hamijoyo L., Abdulah R. Genetic Polymorphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine. Front. Pharmacol. 2022;13:820927. doi: 10.3389/fphar.2022.820927.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.820927</ArticleId><ArticleId IdType="pmc">PMC8972168</ArticleId><ArticleId IdType="pubmed">35370680</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>